Navigation Links
New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis
Date:12/14/2009

EXTON, Pa., Dec. 14 /PRNewswire/ -- BioTrends Research Group, Inc. released ChartTrends®: Biologics in Rheumatoid Arthritis, a syndicated publication offering comprehensive insight into the management of RA patients. The report is based on a comparison of self-reported treatment approaches (as reported by 208 Rheumatologists) with actual patient level data for over 1,000 RA patients who are currently being treated with biologic agents.

To be eligible for the audit, patients had to currently be treated with a biologic agent (UCB's Cimzia, Amgen/Wyeth's Enbrel, Abbott's Humira, Bristol Myers Squibb's Orencia , Centocor-Ortho Biotech's Remicade and Simponi, or Genentech's Rituxan). Each brand was represented by at least 98 patient charts and Rheumatologists were limited to one audit per brand. The aim of ChartTrends is to understand actual treatment algorithms for the biologic brands and to clearly understand the "patient types" being treated with these agents. The audit captured patient demographic variables, co-morbidities, concomitant medications (including DMARD dose and strategy), disease history from diagnosis, biologic initiation, dose titration, brand switching, current clinical status and results from the most recent laboratory and radiographic tests.

Among the audited patients, 30% had their disease classified as severe. 76% of the patients were female, average age was 54 and overall, patients had been followed by their current Rheumatologist for 54 months. The majority of patients are currently prescribed concomitant DMARD therapy, such as methotrexate, although the prevalence varied by brand. While Rheumatologists have reported a more aggressive use of biologic agents, this study confirms these reports by demonstrating that the time between original RA diagnosis and biologic initiation has decreased significantly over the past five years.

First line use was most common with Enbrel and Humira, while Rituxan and Orencia were more commonly later line choices. Despite an indication for use after DMARD failure, more than three quarters of the Orencia patients (n=155) were not started on the therapy until at least one TNF-alpha failure. The two new TNF-alpha treatments, UCB's Cimzia and Centocor Ortho-Biotech's Simponi, are drawing from both biologic naive and switch patients. These new products have significantly higher rates of prior authorization required compared to other biologic agents.

Physicians were also presented with three new agents currently under development for RA, Roche's Actemra, GSK's Arzerra and Pfizer's CP-690. Rheumatologists have greatest familiarity with Actemra, but expressed highest interest in CP-690. The newer TNF-alpha agents (Simponi and Cimzia) along with the alternate mechanism of action agents Orencia and Rituxan appear to be at greatest risk from new entrants into the RA biologic market.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


    Contact:
    Paul Callahan
    610-363-3872
    pcallahan@bio-trends.com

SOURCE BioTrends Research Group, Inc.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014
2. Drug Candidates in Pipeline Offer Potential for Parkinsons Disease Therapeutics Market, Says Frost & Sullivan
3. Reportlinker Adds Medical Fiber Optics - A World Market Analysis
4. Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities
5. Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis
6. Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009
7. Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries)
8. Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis
9. Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective
10. Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis
11. Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president of ... In his new role, Marziani will lead the company,s business development and sales team, ... outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... England , May 24, 2016 ... and Education in Clinical Neurophysiology  Elsevier ... information products and services, today announced the launch of ... an open access journal that focuses on clinical practice ... research, case reports, clinical series, normal values and didactic ...
(Date:5/23/2016)... 2016 Global Paclitaxel Market 2016 ... 12 companies and the Paclitaxel analysis in this study ... industry and its players. This is the ... details the current state of the industry while providing ... applications and industry chain structure. The Paclitaxel market analysis ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... , ... Loma Linda University Health (LLUH) has officially broken ground on the ... 3,000 people looked on as the shovels hit the dirt at the community groundbreaking ... During the program, Richard H. Hart, MD, DrPH, president, LLUH, recapped the history of ...
(Date:5/24/2016)... PA (PRWEB) , ... May 24, 2016 , ... A ... will rely heavily on their access to trusted resources, both in face-to-face interactions and ... Young Men of Color,” researchers concluded that the creative use of mobile digital devices ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Jonathan (Jon) Otterstatter to its board of directors. Otterstatter is co-founder, ... in the development of technological innovations that lead to broad-based healthcare solutions. , ...
(Date:5/24/2016)... ... 2016 , ... As reported by MassGeneral.org, on May 8 – 9, 2016, ... States . The 64-year-old patient who received the transplant had undergone a partial penectomy ... a natural appearance, but also urinary and sexual function for the patient who has ...
(Date:5/24/2016)... ... May 24, 2016 , ... Local ... Republic on September 21, 2016. Dr. Gerard, who holds a Doctorate of Chiropractic ... not-for-profit organization promoting health and wellness in Third World countries where resources are ...
Breaking Medicine News(10 mins):